Intech Investment Management LLC Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Intech Investment Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 3rd quarter, Holdings Channel reports. The fund purchased 8,572 shares of the company’s stock, valued at approximately $282,000.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in Tarsus Pharmaceuticals during the second quarter valued at approximately $61,000. Canada Pension Plan Investment Board acquired a new position in Tarsus Pharmaceuticals during the second quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after purchasing an additional 1,530 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Tarsus Pharmaceuticals by 87.5% in the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after buying an additional 3,379 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after buying an additional 2,879 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Finally, William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $51.64 on Thursday. The stock has a market cap of $1.97 billion, a P/E ratio of -13.36 and a beta of 1.04. The stock has a 50 day simple moving average of $41.75 and a 200 day simple moving average of $33.51. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 1-year low of $15.89 and a 1-year high of $52.99.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.